Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL)

To ascertain the safety of Revlimid® Capsules 2.5 mg or 5 mg under the actual use conditions in patients who received R2 combination therapy with the drug and rituximab for the first time for relapsed or refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL). In particular, this surveillance will collect only information of occurrence state and treatment methods on bone marrow depression (neutropenia), which is specified as a safety specification, as well as on tumor flare, for which attention should be called. 1. Planned registration period 1.5 years 2. Planned surveillance period 3 years from the start of this survey